Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GV101 in Healthy Subjects
NCT05068947Phase 1Completed
- Sponsor
- Graviton Biosciences
- Start
- Sep 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Cerebral cavernous malformation (CCM) and obesity comparing GV101 with Placebo (2 arms). Primary endpoint: Treatment emergent Adverse Events. Started Sep 2021; status: completed.
02
Drugs
TDI01
03
Conditions
Cerebral cavernous malformation (CCM)obesity
Beyond the preview
Go deeper on NCT05068947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068947.